AMAG snaps up rights to new med Intrarosa to compete with Pfizer’s Premarin® vaginal cream

Tracy Staton reporting for FiercePharma.com writes as follows. AMAG Pharmaceuticals has big ambitions for its women’s health business, so it’s snapped up the rights to a new med, Intrarosa, to beef up that portfolio. The company plans to tout Intrarosa’s safety profile to set it apart from established estrogen-based treatments such as Pfizer’s Premarin cream and… Continue reading AMAG snaps up rights to new med Intrarosa to compete with Pfizer’s Premarin® vaginal cream

Premarin Horses Year in Review 2016

Premarin horses (or PMU horses) are the mares and foals cruelly exploited to produce the Premarin® family of drugs made for the relief of menopausal symptoms in women. The key component of these drugs comes from the estrogen rich urine collected from pregnant mares on what are commonly called "pee lines" in the industry. PMU… Continue reading Premarin Horses Year in Review 2016

Horse Fund’s Top Horse Cruelty Issues of 2016

The long awaited Top Horse Cruelty Issues of 2016 and corresponding Year in Review are finally on their way. 2017 started off in a tumultuous fashion and it does not look like it is going to slow down any time soon insofar as horse cruelty issues go, or cruelty to animals in general. It is tragic and we simply do not understand it. We have… Continue reading Horse Fund’s Top Horse Cruelty Issues of 2016

Revenues from Premarin family of drugs falls 3% in 2016

by JANE ALLIN With a fall in prescriptions and market growth, revenues of the Premarin family of drugs have fallen 3% in 2016. So what does a 3% loss in the Premarin family of drugs represent? In 2015, as well as several years previously, these drugs netted about a billion US dollars. The question now… Continue reading Revenues from Premarin family of drugs falls 3% in 2016